Recently, three novel poly-ADP-ribose polymerase (PARP) inhibitors such as olaparib, rucaparib, and niraparib have been approved by the US Food and Drug Administration and European Medicines Agency for the treatment of ovarian cancer caused by the alteration of DNA damage repair pathways [9]. The gene discussed is PARP1; the disease is ovarian cancer.